Who are Jasper Therapeutics, Inc.'s main suppliers?

Jasper Therapeutics, Inc. (JSPRW) key suppliers include: Celldex Therapeutics, Inc., Celldex Therapeutics, Inc., Sanofi, Sanofi. View the full supplier network at chainsifter.com/chain/JSPRW.

Who are Jasper Therapeutics, Inc.'s major customers?

Jasper Therapeutics, Inc. (JSPRW) key customers include: Celldex Therapeutics, Inc., Celldex Therapeutics, Inc., Sanofi, Sanofi. View the full customer network at chainsifter.com/chain/JSPRW.

What sector is Jasper Therapeutics, Inc. in?

Jasper Therapeutics, Inc. (JSPRW) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Jasper Therapeutics, Inc. Supplier List (JSPRW): 4 Verified Suppliers

4Suppliers

4Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Jasper Therapeutics, Inc. (JSPRW) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

9Total relationships

1Distinct source URLs

1High confidence

0.740Average confidence

2026-09-21Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Jasper Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CLDX	Celldex Therapeutics, Inc.	72%	h third parties to market and sell our product candidates, if approved, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues. We have li…
CLDX	Celldex Therapeutics, Inc.	72%	Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPRW graph: h third parties to market and sell our product candidates, if approved, we may not be able to effectively market and…
SNYNF	Sanofi	72%	h third parties to market and sell our product candidates, if approved, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues. We have li…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from JSPRW graph: h third parties to market and sell our product candidates, if approved, we may not be able to effectively market an…

Jasper Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
CLDX	Celldex Therapeutics, Inc.	72%	h third parties to market and sell our product candidates, if approved, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues. We have li…
CLDX	Celldex Therapeutics, Inc.	72%	Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPRW graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from JSPRW graph: h third parties to market and sel…
SNYNF	Sanofi	72%	h third parties to market and sell our product candidates, if approved, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues. We have li…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from JSPRW graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from JSPRW graph: h third parties to market and s…

Jasper Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
JSPRW-DEBT-10465	Warrants outstanding: 0.0001	90%	xbrl warrant detail from xbrl 2025-09-30.

Jasper Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Jasper Therapeutics, Inc..

Jasper Therapeutics, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Jasper Therapeutics, Inc..

Jasper Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
SNYNF	Sanofi	100.00	1	['customer', 'supplier']
CLDX	Celldex Therapeutics, Inc.	100.00	1	['customer', 'supplier']
ANL	Adlai Nortye Ltd.	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2
CRVS	Corvus Pharmaceuticals, Inc.	50.00	2
SVA	Sinovac Biotech Ltd.	50.00	2
CYTK	Cytokinetics, Incorporated	50.00	2
LGND	Ligand Pharmaceuticals Incorporated	50.00	2
CBIO	Crescent Biopharma, Inc.	50.00	2
CCEP	Coca-Cola Europacific Partners PLC	50.00	2
DSGN	Design Therapeutics, Inc.	50.00	2
AZN	AstraZeneca PLC	50.00	2
BIOA	BioAge Labs, Inc.	50.00	2
DBVTF	DBV TECHNOLOGIES	50.00	2
ANRO	Alto Neuroscience, Inc.	50.00	2
EDIT	Editas Medicine, Inc.	50.00	2
FULC	Fulcrum Therapeutics, Inc.	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2
ATOS	Atossa Therapeutics, Inc.	50.00	2
ALXO	ALX Oncology Holdings Inc.	50.00	2

Jasper Therapeutics, Inc. Supply Chain